Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Astellas Pharma's Enterprise Value is MXN450,414 Mil.
Astellas Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was MXN47,367 Mil. Therefore, Astellas Pharma's EV-to-EBIT ratio for today is 9.51.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Astellas Pharma's Enterprise Value is MXN450,414 Mil.
Astellas Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was MXN70,861 Mil. Therefore, Astellas Pharma's EV-to-EBITDA ratio for today is 6.36.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Astellas Pharma's Enterprise Value is MXN450,414 Mil.
Astellas Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was MXN258,059 Mil. Therefore, Astellas Pharma's EV-to-Revenue ratio for today is 1.75.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Astellas Pharma's Enterprise Value is MXN450,414 Mil.
Astellas Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN56,826 Mil. Therefore, Astellas Pharma's EV-to-FCF ratio for today is 7.93.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Astellas Pharma (MEX:4503N) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Astellas Pharma's current Enterprise Value is MXN450,414 Mil.
Astellas Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN47,367 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Astellas Pharma's current Enterprise Value is MXN450,414 Mil.
Astellas Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN70,861 Mil.
Astellas Pharma's current Enterprise Value is MXN450,414 Mil.
Astellas Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN258,059 Mil.
Astellas Pharma's current Enterprise Value is MXN450,414 Mil.
Astellas Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN67,085 Mil.
Astellas Pharma's current Enterprise Value is MXN450,414 Mil.
Astellas Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN56,826 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma Enterprise Value Related Terms
Astellas Pharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:4503N vs LLY, JNJ, ABBV: Enterprise Value Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Astellas Pharma's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of MXN450,414 Mil mean?
Astellas Pharma (MEX:4503N) has a Enterprise Value of MXN450,414 Mil as of Jun. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Enterprise Value too high?
Astellas Pharma's current Enterprise Value is MXN450,414 Mil. Overall, Astellas Pharma has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Enterprise Value compare to LLY and JNJ?
Astellas Pharma's Enterprise Value of MXN450,414 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Enterprise Value is MXN450,414 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (MEX:4503N) is currently considered Fairly Valued. The stock's GF Value™ is MXN246.87, compared to a current price of MXN253.57 — trading 2.7% above its estimated fair value. The current Enterprise Value is MXN450,414 Mil. Astellas Pharma's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Astellas Pharma (MEX:4503N), the current Enterprise Value is MXN450,414 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (MEX:4503N) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued.
The current stock price of MXN253.57 is trading 2.7% above its estimated GF Value™ of MXN246.87.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for MEX:4503N:
Enterprise Value: MXN450,414 Mil
GF Value™: MXN246.87 vs. price of MXN253.57 (2.7% above fair value)
No single metric tells the full story. See the MEX:4503N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
78GF Score
Get the complete analysis for MEX:4503N
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:4503N has been successfully added to your 
